Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings –

– Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker –

Read more at prnewswire.com